Global study tracks new lupus drug in everyday practice

NCT ID NCT06314282

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study follows 200 adults with systemic lupus erythematosus (SLE) who are prescribed anifrolumab as part of their regular treatment. Researchers will observe how well the medication controls lupus symptoms and improves quality of life over one year in real-world clinical settings across multiple countries. The study focuses on practical outcomes like skin symptoms, fatigue, and daily functioning that matter to patients and doctors.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
RECRUITING

Aktobe, Kazakhstan
Research Site
RECRUITING

Almaty, Kazakhstan
Research Site
RECRUITING

Astana, Kazakhstan
Research Site
RECRUITING

Pavlodar, Kazakhstan
Research Site
RECRUITING

Semey, Kazakhstan
Research Site
RECRUITING

Shymkent, Kazakhstan

Conditions

Explore the condition pages connected to this study.

SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)